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In COPD, the activity of the cholinergic system is increased, which is one of
the reasons for the airflow limitation caused by the contraction of airway smooth
muscles. Therefore, blocking the contractive actions with anticholinergics is a useful
therapeutic intervention to reduce the airflow limitation. In addition to the effects of
bronchoconstriction and mucus secretion, accumulating evidence from animal models
of COPD suggest acetylcholine has a role in inflammation. Experiments using muscarinic
M3-receptor deficient mice or M3 selective antagonists revealed that M3-receptors on
parenchymal cells, but not on hematopoietic cells, are involved in the pro-inflammatory
effect of acetylcholine. Recently, combinations of long-acting β2 adrenergic agonists
(LABAs) and long-acting muscarinic antagonists (LAMAs) have become available
for COPD treatment. These dual long-acting bronchodilators may have synergistic
anti-inflammatory effects because stimulation of β2 adrenergic receptors induces
inhibitory effects in inflammatory cells via a different signaling pathway from that
by antagonizing M3-receptor, though these anti-inflammatory effects have not been
clearly demonstrated in COPD patients. In contrast to the pro-inflammatory effects
by ACh via muscarinic receptors, it has been demonstrated that the cholinergic anti-
inflammatory pathway, which involves the parasympathetic nervous systems, regulates
excessive inflammatory responses to protect organs during tissue injury and infection.
Stimulation of acetylcholine via the α7 nicotinic acetylcholine receptor (α7nAChR) exerts
inhibitory effects on leukocytes including macrophages and type 2 innate lymphoid cells.
Although it remains unclear whether the inhibitory effects of acetylcholine via α7nAChR
in inflammatory cells can regulate inflammation in COPD, neuroimmune interactions
including the cholinergic anti-inflammatory pathway might serve as potential therapeutic
targets.
Keywords: acetylcholine, cholinergic anti-inflammatory pathway, chronic obstructive pulmonary disease,
neuroimmune interactions, α7 nicotinic acetylcholine receptor
INTRODUCTION
Acetylcholine (ACh), a neurotransmitter released from nerve terminals of postganglionic
parasympathetic neurons, promote the contraction of airway smooth muscles as well as mucus
secretion via muscarinic type 3 (M3) receptor in the airways (Roffel et al., 1988; Mak and Barnes,
1990). It has been also revealed that non-neuronal cells including airway epithelial cells can
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synthesize and release ACh, which may induce biological
functions in an autocrine or paracrine manner (Proskocil
et al., 2004; Kummer and Krasteva-Christ, 2014). ACh is
significantly involved in the pathogenesis of COPD because
the activity of the cholinergic system is increased in this
disease augmenting the airflow limitation and hypersecretion
(Gross and Skorodin, 1984). In addition to these roles in the
pathogenesis of COPD, accumulating evidence has revealed that
ACh can regulate inflammatory responses. In this review, we
summarize recent literature on the roles of cholinergic pathways
in inflammation, especially focusing on: (1) pro-inflammatory
effects of ACh through mAChRs; (2) possible benefits of the
combinations of long-acting β2 adrenergic agonists (LABAs)
and long-acting muscarinic antagonists (LAMAs) in terms of
regulating inflammation; (3) anti-inflammatory effects of ACh
via the α7 nicotinic acetylcholine receptor (α7nAChR); (4) recent
advances in clarifying neuroimmune interactions that regulating
innate lymphoid cells (ILCs), which could lead to potential
pharmacotherapeutic targets for COPD.
PRO-INFLAMMATORY ACTIONS OF ACh
THROUGH MUSCARINIC ACh
RECEPTORS IN AIRWAYS
In addition to the role of ACh in neurotransmission, the
activation of muscles and mucus secretion, accumulating
evidence from animal studies using muscarinic antagonists
or subtype-specific deficient mice has suggested that ACh
can augment airway inflammation through muscarinic
ACh receptors. Tiotropium, one of the LAMAs with higher
selectivity for M3 receptors, inhibited pulmonary neutrophilic
inflammation and the release of leukotriene B4 (LTB4),
interleukin-6 (IL-6), keratinocyte-derived chemokine(KC;
IL-8 in humans), monocyte chemotactic protein-1 (MCP-1),
macrophage inflammatory protein-1alpha and -2 (MIP-1α
and MIP-2), and tumor necrosis factor alpha (TNF-α) in a
mouse COPD model induced by cigarette smoke (Wollin and
Pieper, 2010). Tiotropium also attenuated neutrophil infiltration
and the elevation of IL-6 and TNF-α in cigarette smoke and
virus-exposed mice (Bucher et al., 2016). Glycopyrronium,
another M3-selective LAMA, attenuated the accumulation of
neutrophils and macrophages and the elevation of inflammatory
cytokines and chemokines induced by both acute and subchronic
cigarette smoke exposure (Shen et al., 2014; Hsiao et al.,
2018). Aclidinium bromide, another M3-selective LAMA,
also attenuated neutrophilic infiltration in the alveolar septa
in a cigarette smoke–exposed guinea pig model of COPD
(Dominguez-Fandos et al., 2014). Although these LAMAs are
kinetically selective for M3 receptors due to their dissociation
time from M3 being longer than that from M2 or M1, the
binding affinity of these agents for M1, M2, and M3 are similar
and have limited selectivity (Casarosa et al., 2009), meaning
that it is still unclear which muscarinic receptor subtype was
critical for the pro-inflammatory effects in a cigarette smoke-
exposed animal model of COPD. To answer this question,
gene-targeting in mice for each subtype of muscarinic receptor
was employed. M3 receptor-deficient mice showed a decrease
in both neutrophil accumulation in the lungs and the release
of KC, a neutrophil chemotactic factor, in an acute cigarette
smoke-exposed mouse model (Kistemaker et al., 2013). In
contrast to M3 receptor-deficient mice, M2 receptor-deficient
mice showed an increase in both neutrophil infiltration in
the airspaces and the release of KC after exposure to cigarette
smoke (Kistemaker et al., 2013). Because the M2 receptor
is located on the pre-junctions of pre- and post-ganglionic
pulmonary parasympathetic nerves and acts as a feedback
inhibitory receptor limiting acetylcholine release (Fryer and
Maclagan, 1984; Faulkner et al., 1986; Minette and Barnes,
1988), the levels of ACh are increased in the airway of M2
receptor-deficient mice causing an enhancement of neutrophilic
inflammation via the M3 receptor. Mice deficient in the
M1 receptor, which is expressed on parasympathetic ganglia
and mediate neurotransmission, also shows a remarkable
enhancement of neutrophil inflammation after cigarette
smoke-exposure (Kistemaker et al., 2013). This seems to be
paradoxical because a M1 receptor deficiency would cause a
reduction of acetylcholine in the airway, resulting the reduction
of inflammation. Because M1 receptors are also expressed
on airway epithelial cells and regulate electrolyte and water
secretion (Ishihara et al., 1992), a hypothesis explaining this
paradox is that the clearance of smoke particles is impaired in M1
deficient mice. In vitro cell culture experiments also supported
the pro-inflammatory actions of ACh thorough muscarinic
receptors on airway parenchymal cells and inflammatory cells
(Table 1). Because M3 receptors are expressed in various
types of cells including parenchymal cells and hematopoietic
cells in airways (Table 1), the question has arisen whether
the pro-inflammatory effects of ACh via M3 receptors are
mediated mainly by parenchymal cells or inflammatory cells.
To answer this question, bone marrow chimeric mice were
established. This investigation revealed that the accumulation
of neutrophils in the airways was inhibited in M3 receptor-
deficient mice with wild-type bone marrow, whereas wild-type
mice with M3 receptor-deficient bone marrow showed a
comparable increase in neutrophil accumulation, suggesting
that M3 receptors of the airway parenchymal cells are primarily
involved in the pro-inflammatory effects of ACh during
cigarette smoke-induced inflammation (Kistemaker et al.,
2015b).
Although there is accumulating evidence for a significant
role of ACh as a pro-inflammatory factor in COPD as well as
clinical evidence showing that LAMAs decrease exacerbations
of COPD, stronger evidence for its pro-inflammatory role in
COPD patients is still limited. Treatment with tiotropium in
COPD patients decreased the annual rate of exacerbations.
However, the amount of IL-6 and myeloperoxidase in sputum
did not decrease. Moreover, the concentration of IL-8 and
MMP-9 increased in the sputum of the group treated with
tiotropium (Powrie et al., 2007; Perng et al., 2009). Tiotropium
treatment also did not significantly decrease IL-6 or C-reactive
protein in the serum (Powrie et al., 2007). This is possibly
due to the fact that tiotropium decreased the amount of
mucus secretion, causing a higher concentration of the
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TABLE 1 | Pro-inflammatory effects of ACh on parenchymal and leukocytes via muscarinic receptors.
Type of cells Type of receptors Actions Reference
Parenchymal cells
Epithelial cells M1, M2, M3 Inducing the release of IL-8 Profita et al., 2008
Stimulating the release of LTB4 Profita et al., 2011
Augmenting IL-17A-induced release of IL-8 Anzalone et al., 2016
Fibroblasts M1, M2, M3 Augmenting IL-1β-induced release of IL-6 and IL-8 Costa et al., 2014
Smooth muscle cells M2, M3 Stimulating the release of IL-6 and IL-8 Gosens et al., 2009
Leukocytes
Macrophages M1, M2, M3, M4, M5 Stimulating the release of LTB4 Sato et al., 1998; Buhling et al., 2007;
Koarai et al., 2012
Neutrophils M2, M3, M4, M5 Stimulating the release of IL-8 Milara et al., 2016
Augmenting inflammatory mediator and matrix
metalloproteinase release induced by LPS and cigarette
smoke extract
Milara et al., 2016
Mast cell M1, M3, M4, M5 Inhibiting the release of histamine Reinheimer et al., 2000
Lymphocytes M1, M2, M3, M4, M5 Augmenting the production of antibodies and cytokines Fujii et al., 2007
mediators in sputum. It has been reported that targeted
lung denervation of parasympathetic nerves in patients with
COPD induces a reduction of neutrophil accumulation and
inflammatory mediators including IL-8 (Kistemaker et al.,
2015a). This is the first direct evidence showing that ACh
acts a pro-inflammatory factor in actual COPD patients.
Further investigations including histological evaluations
by bronchial biopsy will be needed to elucidate whether
antimuscarinic drugs actually effect inflammation in COPD
patients.
POSSIBLE BENEFITS OF THE
COMBINATIONS OF LABAs AND LAMAs
IN TERMS OF REGULATING
INFLAMMATION DURING COPD
Several clinical studies have reported that the combination
of LABA and LAMA reduces exacerbations more than the
use of LABA or LAMA alone (Wedzicha et al., 2013;
Calverley et al., 2018). LABA/LAMA combinations decrease
hyperinflation (Beeh et al., 2014; Vincken et al., 2014) and
symptom severity (Mahler et al., 2014; Buhl et al., 2015;
Oba et al., 2016), and improve sputum clearance (Powrie
et al., 2007; Meyer et al., 2011; Tagaya et al., 2016), all of
which may contribute to decreasing exacerbations. Although
the effects of the LABA/LAMA combination therapy against
inflammation have not been demonstrated in patients with
COPD, nor has LAMA or LABA alone, several mechanisms are
possibly involved in the synergistic actions of the LABA/LAMA
combination against inflammation (Figure 1). One of the
possible mechanisms is that LABA and LAMA synergistically
inhibit the release of non-neurogenic acetylcholine from
bronchial epithelial cells. A recent report showed that, although
single administration of glycopyrronium or indacaterol did
not modify the release of acetylcholine from primary human
bronchial epithelial cells, the combination of glycopyrronium
and indacaterol significantly reduced the release of acetylcholine
(Cazzola et al., 2016). This effect may originate through the
modulation of organic cation transporter 1, a transporter
for the release of acetylcholine from airway epithelial cells
(Salomon et al., 2015). This mechanism may contribute
to the anti-inflammatory effects by reducing the levels of
acetylcholines, which have pro-inflammatory effects via M3
receptors. Another possible mechanism is that LABA and
LAMA synergistically inhibit the release of pro-inflammatory
factors from parenchymal cells or inflammatory cells. Tiotropium
or olodaterol attenuates the production of reactive oxygen
species (ROS), NOX-4 protein expression, and IL-8 release
from 16HBE cells induced by cigarette smoke extract (CSE),
and the combination of LABA and LAMA provides stronger
effects compared to LAMA or LABA alone (Albano et al.,
2018). Tiotropium or olodaterol reduces neutrophil adhesion
and the expression of macrophage-1 antigen (MAC-1) adhesion
protein on neutrophils stimulated by sputum supernatants from
patients with COPD. The combination of these agents augments
these effects. Olodaterol attenuates neutrophil accumulation and
pro-inflammatory mediators in the airway of cigarette smoke
or LPS-induced murine and guinea pig lung inflammation
models, and also attenuates the release of TNF-α from blood
leukocytes and reduces CD11b adhesion molecule expression
on granulocytes in vitro (Wex et al., 2015). Recent studies
showed that β2-receptor agonists attenuated the release of
TNF-α and MCP-1 induced by LPS from a mouse macrophage
cell line by mediating the cAMP-dependent inhibition of
ERK and p38MAPK pathways (Keranen et al., 2016, 2017).
Because a M3 mAChR antagonist attenuated the production
of TNF-α induced by LPS from alveolar macrophages via
mediating the NF-κB signaling pathway, combinations of these
drugs may possibly inhibit the release of pro-inflammatory
factors synergistically also in terms of intracellular signaling
(Xu et al., 2012). To confirm these suggested mechanisms
in the synergistic effects by the LABA/LAMA combination
in COPD patients, further clinical investigations will be
needed.
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FIGURE 1 | Possible mechanisms of synergistic actions of the LABA/LAMA combination against inflammation. (A) Synergistic inhibitory effect of LABA/LAMA
against ACh release from airway epithelial cells. Signaling via β2AR inhibits the function of OCT1, a transporter for the release of acetylcholine from airway epithelial
cells, whereas signaling via M3 possibly upregulates the function of OCT1. Therefore, the LABA/LAMA combination synergistically inhibits the release of ACh.
(B) Synergistic inhibitory effect of LABA/LAMA against the production of inflammatory mediators. Signaling via β2AR activates AC-cAMP-PKA signaling pathway.
PKA inhibits ERK and p38MAPK pathways. In contrast, signaling via M3 activates PKC, which results in the activation of NF-κB. The combination of LABA and
LAMA therefore possibly inhibits the production of pro-inflammatory mediators synergistically via inhibiting both MAPK and NF-κB pathways. ACh, acetylcholine; AC,
adenylate cyclase; β2AR, beta-2 adrenergic receptor; cAMP, cyclic adenosine monophosphate; CHT1, high-affinity choline transporter 1; ERK, extracellular
signal-regulated kinase; LABA, long-acting β2 agonist; LAMA, long-acting muscarinic antagonist; MAPK, mitogen-activated protein kinase; M3, acetylcholine
muscarinic M3 receptor; NF-κB, nuclear factor-kappa B; OCT1, organic cationic transporter 1; PKA, protein kinase A; PKC, protein kinase C.
ANTI-INFLAMMATORY EFFECTS OF ACh
VIA THE α7 NICOTINIC ACETYLCHOLINE
RECEPTOR (α7nAChR)
In contrast to the pro-inflammatory effects by ACh through
muscarinic ACh receptors, it has been elucidated that there
is a cholinergic anti-inflammatory pathway which includes
parasympathetic nerves that regulate the inflammatory responses
to maintain the body during tissue injury and infection. An
investigation with gene-deficient animal models revealed that
α7nAChR on splenic macrophages was critical for attenuating
the inflammatory response by ACh in an LPS-induced animal
septic model (Wang et al., 2003). Further investigations revealed
that the efferent vagus nerve stimulates sympathetic neurons of
the splenic nerve, and then NE produced by the splenic nerve
stimulates splenic T cells expressing β2-adrenergic receptors
causing the production of ACh, which can bind to α7nAChR
on splenic macrophages (Rosas-Ballina et al., 2008; Rosas-Ballina
et al., 2011; Vida et al., 2011).
In airways, ACh is derived from parasympathetic
postganglionic neurons or non-neuronal cells including epithelial
cells and can possibly bind to α7nAChR on macrophages
and other inflammatory cells attenuating inflammation. An
experiment using a mouse model of acid-induced acute lung
injury or sepsis-induced acute lung injury showed that α7nAChR
is expressed on alveolar macrophages and neutrophils, and
activation of α7nAChR by nicotine or PNU-282987, a specific
agonist, reduced the inflammatory responses and attenuated
the severity of lung injury, whereas the lung injury became
worse in α7nAChR-deficient mice (Su et al., 2007, 2010). In
a rodent lung injury model of ventilator-induced lung injury,
intestinal ischemia-reperfusion, severe acute pancreatitis and
cardiopulmonary bypass-induced lung ischemia-reperfusion, the
activation of α7nAChR provided protective effects against lung
injury (Dos Santos et al., 2011; He et al., 2016; Ma et al.,
2016; Ge et al., 2017). The exact mechanism by which the
activation of α7nAChR induced anti-inflammatory effects is still
not clear. The activation of a7 nAChR by a specific agonist in
monocytes epigenetically increases histone deacetylation, which
decreases in the NF-κB p65 activity of transcription factors
including NF-κB, and the transcription of pro-inflammatory
cytokine genes (Yang et al., 2017). In E. coli and LPS-induced
lung injury mouse models, vagotomy augmented the lung
recruitment of α7nAChR+ CD11b+ monocytes and neutrophils.
The activation of α7nAChR by an agonist suppressed the
recruitment of α7nAChR+ CD11b+ monocytes and neutrophils.
The phosphorylation of serine 473 of AKT1 via α7nAChR
signaling is involved in the attenuation of the lung recruitment
of these inflammatory cells (Zhao et al., 2017). It has been also
reported that activation of α7nAChR attenuates the polarization
of alveolar macrophages to the pro-inflammatory M1 phenotype,
whereas M2 macrophages were increased in an LPS-induced lung
injury model (Pinheiro et al., 2017; Wang et al., 2018).
In contrast to acute lung injury models showing the protective
effect of α7nAChR against inflammation, there is a report
suggesting that signaling via α7nAChR may worsen fibrosis
in the lungs. In a mouse bleomycin-induced lung fibrosis
model, the severity of lung fibrosis, including histological
scoring and the expression of fibrogenic genes, was attenuated
in α7nAChR deficient mice. The activation of α7nAChR by
GTS-21 (an α7nAChR agonist) increased the TGF-β-induced
phosphorylation of Smad2/3 and transcription of fibrogenic
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genes in lung fibroblasts (Sun et al., 2017). Another report
showed that nicotine stimulated collagen type I mRNA and
protein expression in primary lung fibroblasts. This effect
of nicotine was not observed in α7nAChR-deficient primary
lung fibroblasts. In vivo administration of nicotine increased
collagen type I expression in the wild type, but not in
α7nAChR-deficient mice (Vicary et al., 2017). These reports
suggest that α7nAChR signaling in lung fibroblasts is involved
in the pathogenesis of fibrotic lung diseases and airway
remodeling.
It has been reported that airway epithelial cells also express
α7nAChR (Su et al., 2007; Gahring et al., 2017). Reporter
gene analyses for α7nAChR expression in genetically modified
mice revealed that α7nAChRs are expressed in club cells and
alveolar type II cells as well as alveolar macrophages (Gahring
et al., 2017). α7nAChRs are likely involved in the regulation
of proliferation, ion transport and responses to inflammatory
stimuli (Nastrucci and Russo, 2012; Maouche et al., 2013; Gahring
et al., 2017). Moreover, α7nAChRs are expressed in non-small
cell lung cancer cells and participate in tumor growth and
epidermal-mesenchymal transition (Chernyavsky et al., 2015;
Schaal and Chellappan, 2016; Bordas et al., 2017; Zhang et al.,
2017; Mucchietto et al., 2018). Therefore, these tumor-promoting
actions as well as pro-fibrotic actions via α7nAChRs could be
serious barriers to employing α7nAChR agonists to attenuate
inflammation in chronic inflammatory diseases such as COPD
and asthma, which require continuous drug administration.
RECENT ADVANCES IN CLARIFYING
THE NEUROIMMUNE INTERACTIONS
REGULATING INNATE LYMPHOID CELLS
It has been revealed that ILCs, which originate from common
lymphoid cells but do not have antigen receptors, exist in
various tissues of mammals including human, and can produce
various cytokines in response to various stimuli including
alarmins. ILCs are classified into type 1, type 2, and type 3
ILCs according to their functions and the cytokines produced
(Vivier et al., 2018). Recently, neurotransmitters including
acetylcholine have been shown to likely participate in the
regulation of proliferation and activation of ILCs (Figure 2). Type
2 innate lymphoid cells (ILC2s) produce significant amounts of
Th2 cytokines and participate in airway allergic inflammation.
A recent report described that α7nAChRs are expressed on
ILC2s. The activation of α7nAChRs on ILC2s suppresses
IL-5 and IL-13 production in ILC2s and ameliorates ILC2-
induced airway hyperreactivity. α7nAChR agonist attenuates
the expression of GATA3 and NF-κB in ILC2s as well as the
proliferation of ILC2s. The activation of α7nAChR by an agonist
also prevents human ILC2 mediated airway hyperreactivity
as well as type 2 cytokine production and eosinophilic
inflammation. These observations may suggest a protective role
of α7nAChR signaling in ILC2s against ILC2-mediated allergic
inflammation and the possibility that α7nAChR could be a
potential therapeutic target for the treatment of ILC2-mediated
asthma.
Other recent studies have shown that the neuropeptide
neuromedin U (NMU) released from neural cells activates ILC2s
and amplifies ILC2-driven allergic inflammation (Cardoso et al.,
2017; Klose et al., 2017; Wallrapp et al., 2017). In an airway
allergic mouse model induced by intranasal administration of
IL-25 and IL-33, single-cell RNA sequencing analyses were
performed to profile mouse lung-resident ILCs and revealed
that NMUR1, a receptor for NMU, was specifically expressed on
ILC2s (Wallrapp et al., 2017). Immunofluorescence microscopic
analysis suggested that ILC2s were likely located close to
nerve fibers. Sensory neurons in the dorsal root ganglia, but
not parasympathetic neurons in the nodose/jugular ganglion,
expressed NMU. IL-13 induced the upregulation of NMU in
cultured dorsal root ganglia neurons. NMU can activate ILC2s
and induce type 2 cytokine productions in vitro. Intranasal co-
administration of NMU with IL-25 strongly amplified airway
allergic inflammation. Moreover, NMUR1-deficient mice showed
an attenuation of both the ILC2 frequency and effector
function during airway inflammation from house dust mites.
These findings indicated that NMU derived from sensory
neurons innervated into airways can activate ILC2s, and this
newly identified neuroimmune interaction is involved in the
modulation of airway allergic inflammation (Wallrapp et al.,
2017).
Another study using RNA sequencing analyses of ILC2s
revealed that mouse and human ILC2s express β2-adrenergic
receptor (β2AR) (Moriyama et al., 2018). β2AR-deficient
mice showed amplified ILC2 activation and airway allergic
inflammation induced by intranasal stimulation with IL-33 or
Alternaria extract, whereas the administration of β2 agonist
attenuated the ILC2-responses and allergic inflammation. RNA-
sequence analyses further showed that β2AR signaling pathway
inhibits the cell proliferation and effector function of ILC2s.
This study suggests that sympathetic adrenergic neurons that
innervate the airways negatively regulate ILC2s via β2AR.
Pulmonary neuroendocrine cells (PNECs) are a unique but
poorly understood cell population in the lungs. Although it
has been reported that PNECs are increased in pulmonary
diseases, including small-cell lung cancer, the precise role of
PNECs in pulmonary diseases remains unknown. A recent report
showed that PNECs have a significant role in the mucosal
type 2 response in models of allergic asthma (Sui et al., 2018).
PNECs act through calcitonin gene-related peptide (CGRP) to
stimulate ILC2s and induce downstream immune responses,
and also act through GABA to induce goblet-cell hyperplasia.
These new findings demonstrated a novel neuroimmune system
in the airway that augments the type 2 allergic response. It
is still unknown how PNECs are activated following allergen
challenge. PNECs are innervated by sensory afferents mostly
from nodose ganglion neurons and vagal efferents, and this
innervation of PNEC is required for the increased production of
GABA (Barrios et al., 2017), suggesting that stimulating efferent
neurons that innervate PNECs may be involved in the activation
of PNECs.
Compared with ILC2s, neuroimmune interactions that
regulate the other ILCs, ILC3 and ILC1, in airways remain
unclear, although it has been reported that their possible
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FIGURE 2 | Neuroimmune interaction regulating innate lymphoid cells. (A) Glucocorticoids derived from hypothalamic-pituitary-adrenal axis stimulated by
inflammatory mediators during systemic inflammation bind to GRs in ILC1s, which inhibits the release of IFN-γ. (B) The activation of ILC2s by epithelial alarmin
cytokines is inhibited by ACh derived from parasympathetic neurons and possibly non-neuronal cells via α7nAChR, or NA derived from sympathetic neurons via
β2AR. In contrast, neuromedin U derived from DRG sensory neurons or CGRP derived from PNECs augments the activation of ILC2s via NMUR1 or CRLR,
respectively. (C) RET ligand derived from glial cells or acetylcholine derived from parasympathetic neurons arguments the proliferation and activation ILC3s via RET
or muscarinic receptors, respectively. α7nAChR, α7 nicotinic acetylcholine receptor; ACh, acetylcholine; APC, antigen-presenting cell; β2AR, beta-2 adrenergic
receptor; CGRP, calcitonin gene-related peptide; CRLR, calcitonin receptor-like receptor; DRG, dorsal root ganglia; GCs, glucocorticoids; IFN-γ, interferon-gamma;
ILCs, innate lymphoid cells; MR, acetylcholine muscarinic receptor; NA, norepinephrine; NMU, neuromedin U; NMUR1, neuromedin-U receptor 1; PNEC, pulmonary
neuroendocrine cell; TNF-α, tumor necrosis factor-alpha.
interactions may regulate other ILCs during systemic
inflammation or inflammation of other organs. In gut, ILC3s
express RET, a neuroregulatory receptor, and are localized
close to glial cells expressing RET-ligands. Glial cells sense
microenvironmental changes and release RET-ligands, causing
ILC3 activation and the release of IL-22 (Ibiza et al., 2016).
In a mouse E. coli peritonitis model, acetylcholine, probably
via muscarinic receptors, upregulates ILC3 numbers, causing
peritoneal macrophage production of a protective mediator,
protectin conjugates in tissue regeneration 1 (PCTR1), and
accelerate the resolution of inflammation induced by bacterial
infection (Dalli et al., 2017). In a study using an LPS-induced
septic model, group 1 ILCs expressed glucocorticoid receptor and
stimulation with glucocorticoids prevented IFN-γ production
by ILC1s, which cause the development of IL-10-dependent
tolerance to endotoxin (Quatrini et al., 2017).
These on-going investigations of neuroimmune crosstalk,
including the cholinergic pathways in airways, may lead to new
potential therapeutic targets not only for acute inflammation
but also for chronic inflammatory respiratory diseases including
COPD. However, we should also note that neurotransmitters
participating in neuroimmune interactions also have other
fundamental functions including neurotransmission, which
means blocking these neurotransmitters could possibly cause
critical adverse effects. Accordingly, we also have to take into
account the delivery system for candidate drugs that regulate
neuroimmune interactions.
CONCLUSION
Accumulating evidence from in vitro and in vivo animal
model investigations suggests that acetylcholine derived
from parasympathetic neurons and non-neuronal cells can
modulate airway inflammation. The pro-inflammatory actions of
acetylcholine, mainly via M3 receptors, and possible synergistic
anti-inflammatory effects of β2AR signaling may provide
evidence for the benefit of treatment with LAMA or the
combination of LABA/LAMA, although it remains unclear
whether these treatments really have anti-inflammatory effects
in COPD patients. Therefore, further clinical investigation
will be needed to clarify the anti-inflammatory effects. Anti-
inflammatory effects by acetylcholine via α7nAChR, which may
modulate lung inflammation, have been revealed especially
in systemic inflammation. However, we should be careful
about other biological effects of α7nAChR signaling, including
pro-fibrotic actions and tumor-promoting actions in terms of
therapeutic utilization for chronic respiratory diseases including
COPD. Recent on-going studies has revealed critical interactions
between ILCs and neurotransmitters including acetylcholine.
These newly found neuroimmune interactions may reveal
therapeutic targets for airway inflammatory diseases. Further
investigations will reveal novel effects of neurotransmitters
including acetylcholine on immune systems and inflammation
and may provide new therapeutic clues for clarifying airway
inflammatory diseases such as COPD.
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